159 related articles for article (PubMed ID: 35788063)
1. Delayed-Type Heparin Allergy: Intravenous Tolerance Despite Inflammatory Skin Reaction After Subcutaneous Injection.
Trautmann A; Grän F; Stoevesandt J
J Allergy Clin Immunol Pract; 2022 Nov; 10(11):2977-2983.e1. PubMed ID: 35788063
[TBL] [Abstract][Full Text] [Related]
2. [A study of 19 cases of allergy to heparins with positive skin testing].
Phan C; Vial-Dupuy A; Autegarden JE; Amsler E; Gaouar H; Abuaf N; Pecquet C; Francès C; Soria A
Ann Dermatol Venereol; 2014 Jan; 141(1):23-9. PubMed ID: 24461090
[TBL] [Abstract][Full Text] [Related]
3. Heparin allergy: delayed-type non-IgE-mediated allergic hypersensitivity to subcutaneous heparin injection.
Trautmann A; Seitz CS
Immunol Allergy Clin North Am; 2009 Aug; 29(3):469-80. PubMed ID: 19563992
[TBL] [Abstract][Full Text] [Related]
4. Delayed-type hypersensitivity skin reactions caused by subcutaneous unfractionated and low-molecular-weight heparins: tolerance of a new recombinant hirudin.
Koch P; Münssinger T; Rupp-John C; Uhl K
J Am Acad Dermatol; 2000 Apr; 42(4):612-9. PubMed ID: 10727306
[TBL] [Abstract][Full Text] [Related]
5. Fondaparinux: a suitable alternative in cases of delayed-type allergy to heparins and semisynthetic heparinoids? A study of 7 cases.
Jappe U; Juschka U; Kuner N; Hausen BM; Krohn K
Contact Dermatitis; 2004 Aug; 51(2):67-72. PubMed ID: 15373846
[TBL] [Abstract][Full Text] [Related]
6. Low allergenic potential with fondaparinux: results of a prospective investigation.
Schindewolf M; Scheuermann J; Kroll H; Garbaraviciene J; Hecking C; Marzi I; Wolter M; Kaufmann R; Boehncke WH; Lindhoff-Last E; Ludwig RJ
Mayo Clin Proc; 2010 Oct; 85(10):913-9. PubMed ID: 20843983
[TBL] [Abstract][Full Text] [Related]
7. Molecular weight determines the frequency of delayed type hypersensitivity reactions to heparin and synthetic oligosaccharides.
Ludwig RJ; Schindewolf M; Alban S; Kaufmann R; Lindhoff-Last E; Boehncke WH
Thromb Haemost; 2005 Dec; 94(6):1265-9. PubMed ID: 16411404
[TBL] [Abstract][Full Text] [Related]
8. The complex clinical picture of side effects to anticoagulation.
Trautmann A; Seitz CS
Med Clin North Am; 2010 Jul; 94(4):821-34, xii-iii. PubMed ID: 20609865
[TBL] [Abstract][Full Text] [Related]
9. Successful desensitization with un-fractionated heparin in a patient with heparin allergy and tolerance to fondaparinux.
Kavut AB; Koca E
Asian Pac J Allergy Immunol; 2012 Jun; 30(2):162-6. PubMed ID: 22830297
[TBL] [Abstract][Full Text] [Related]
10. Immediate Type Hypersensitivity to Heparins: Two Case Reports and a Review of the Literature.
Cesana P; Scherer K; Bircher AJ
Int Arch Allergy Immunol; 2016; 171(3-4):285-289. PubMed ID: 28049195
[TBL] [Abstract][Full Text] [Related]
11. Delayed-type hypersensitivity skin reactions due to heparins and heparinoids. Tolerance of recombinant hirudins and of the new synthetic anticoagulant fondaparinux.
Koch P
Contact Dermatitis; 2003 Dec; 49(6):276-80. PubMed ID: 15025697
[TBL] [Abstract][Full Text] [Related]
12. Tolerance to intravenous heparin in patients with delayed-type hypersensitivity to heparins: a prospective study.
Gaigl Z; Pfeuffer P; Raith P; Bröcker EB; Trautmann A
Br J Haematol; 2005 Feb; 128(3):389-92. PubMed ID: 15667543
[TBL] [Abstract][Full Text] [Related]
13. Management of allergy to heparins in postoperative care: subcutaneous allergy and intravenous tolerance.
Seitz CS; Brocker EB; Trautmann A
Dermatol Online J; 2008 Sep; 14(9):4. PubMed ID: 19061586
[TBL] [Abstract][Full Text] [Related]
14. Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism.
Robertson L; Strachan J
Cochrane Database Syst Rev; 2017 Feb; 2(2):CD006771. PubMed ID: 28195640
[TBL] [Abstract][Full Text] [Related]
15. Adverse skin reactions to low molecular weight heparins: frequency, management and prevention.
Wütschert R; Piletta P; Bounameaux H
Drug Saf; 1999 Jun; 20(6):515-25. PubMed ID: 10392668
[TBL] [Abstract][Full Text] [Related]
16. Clinical Patterns of Heparin Allergy: Cross-reactivity Between Low-Molecular-Weight Heparins and Unfractionated Heparins.
Rodríguez-Fernández A; Sánchez-Domínguez M; Torrado-Español I; Noguerado-Mellado B; Rojas-Pérez-Ezquerra P
J Investig Allergol Clin Immunol; 2019 Apr; 29(2):132-134. PubMed ID: 31017110
[No Abstract] [Full Text] [Related]
17. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.
Akl EA; Kahale L; Neumann I; Barba M; Sperati F; Terrenato I; Muti P; Schünemann H
Cochrane Database Syst Rev; 2014 Jun; (6):CD006649. PubMed ID: 24945634
[TBL] [Abstract][Full Text] [Related]
18. Delayed-type hypersensitivity to low molecular weight heparins and heparinoids: cross-reactivity does not depend on molecular weight.
Grims RH; Weger W; Reiter H; Arbab E; Kränke B; Aberer W
Br J Dermatol; 2007 Sep; 157(3):514-7. PubMed ID: 17573880
[TBL] [Abstract][Full Text] [Related]
19. Unfractionated or low-molecular weight heparin for induction of remission in ulcerative colitis.
Chande N; McDonald JW; Macdonald JK; Wang JJ
Cochrane Database Syst Rev; 2010 Oct; (10):CD006774. PubMed ID: 20927749
[TBL] [Abstract][Full Text] [Related]
20. Non-immediate heparin and heparinoid cutaneous allergic reactions: a role for fondaparinux.
Tan E; Thompson G; Ekstrom C; Lucas M
Intern Med J; 2018 Jan; 48(1):73-77. PubMed ID: 29314514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
